TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Sodium Retention in Liver Cirrhosis With Dexamethasone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with established liver cirrhosis (biopsy or biochemically)~* hepatorenal syndrome type 1 or 2 (with a serum creatinin \>175 umol/l)~* age between 18 and 75~* no bacterial infection~* no cardiovascular or extrahepatic disease (end of life)~* no structural kidney disease~* no hepatocellular carcinoma~Exclusion Criteria:~* age under 15 or over 75~* treatment with corticosteroids (dexamethasone included)~* bacterial infection~* cardiovascular or extrahepatic disease (end of life)~* structural kidney disease (indicated by hematuria, proteinuria)~* hepatocellular carcinoma~* mental disability

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nerve Burial for Preventing Neuralgia After Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have symptomatic knee osteoarthritis under consideration for total knee arthroplasty~* Must be willing to undergo randomization~Exclusion Criteria:~* Age \<18 or \>80 years~* Known pre-operative diagnosis of neuralgia, complex regional pain syndrome, or neuropathy, about the operative lower extremity~* Known pre-operative psychiatric disorder requiring medication~* Previous surgery about the operative knee~* BMI \> 40 kg/m2 (potential increased risk of soft tissue dissection through adipose)~* Ongoing pre-operative narcotic use in excess of 20 mg morphine equivalents per day for at least one month or pre-operative intravenous drug use (increased potential for complex regional pain syndrome and neuralgia, increased likelihood to require greater post-operative analgesia)~* Ongoing pre-operative use of neuropathic pain medications (gabapentin, pregabalin, amitriptyline, etc.)~* Medical comorbidities (American Society of Anesthesiologists grade \> 3 or deemed unfit by consulting internist) precluding elective TKA~* Significant language barrier (reading comprehension less than 8th grade reading level) or mental condition precluding accurate self-assessment of knee pain or function.~* Severe medication allergies to permissible post-operative analgesics (acetaminophen, tramadol, oxycodone, oxycontin, dilaudid)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Standard total knee arthroplasty performed through medial parapatellar approach
- Intervention (Type: EXPERIMENTAL): Total knee arthroplasty performed through medial parapatellar approach with identification, ligation, and burial of saphenous nerve branches

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants who completed the 24-week treatment period of Study GLPG1690-CL-204 and who according to the investigator's judgment may benefit from long-term treatment with GLPG1690.~Exclusion Criteria:~* Any condition or circumstances that, in the opinion of the investigator, may make a participant unlikely or unable to complete the study or comply with study procedures and requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GLPG1690 600 mg (Type: EXPERIMENTAL): Participants who received GLPG1690 600 milligrams (mg) in the GLPG1690-CL-204 (NCT03798366) study received GLPG1690 600 mg orally once daily up to 91 weeks.
- Placebo (Type: EXPERIMENTAL): Participants who received placebo matched to GLPG1690 in the GLPG1690-CL-204 (NCT03798366) study received GLPG1690 600 mg orally once daily up to 91 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Ketamine Versus Intramuscular Ketamine for Procedural Sedation in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* pediatric patients age 2 to 17 years old~* have a laceration of 4 cm on the face or 7 cm on the remainder of the body~* Require procedural sedation to repair the laceration~Exclusion Criteria:~* Patients with abnormal nasal physiology which would not allow for adequate medication delivery~* Unable to have a guardian present to consent on their behalf~* Allergy to ketamine~* Significant cardiac history (myocardial ischemia, heart failure, arrhythmias)~* Presenting with a head injury associated with possible intracranial hypertension~* Pregnancy~* Lacerations that require repair from a consult service

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Intranasal Ketamine (Type: EXPERIMENTAL): None
- Intramuscular Ketamine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients 20 years of age or older at enrollment who are able to visit~2. Patients with chronic stable angina who have severe coronary stenosis wich require PCI.~3. Patients who have at least one coronary plaque (≧ 500μm in thickness or % plaque of 20% or more) at the non-culprit vessels.~4. Patients with hyperuricemia, who have a serum uric acid level \>7.0mg/dL within 2 months prior to enrollement.~5. Patients who personally given written informed consent to participate in this study.~Exclusion Criteria:~1. Patients who had undergone previous PCI for the lesion under investigation.~2. Patients with gouty tophus, or patients with subjective symptoms of gouty arthritis within 1 year prior to enrollment.~3. Patients with a previous history of hypersensitivity to febuxostat or allopurinol.~4. Patients with serious kidney disease, Acute kidney disease, nephrotic syndrome, dialysis patients, kidney transplant patients, eGFR \< 30 mL/min/1.73m2, etc.~5. Patients with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) 2 or more times the upper limit of normal.~6. Patients on any of the following medications at enrollment Mercaptopurine hydrate, azathioprine, vidarabine, or didanosine.~7. Patients who receive any of the following medications for the treatment of hyperuricemia within 1 month prior to enrollment Allopurinol, benzbromarone, probenecid, bucolome, topiroxostat, or febuxostat.~8. Patients otherwise judged by the principal or sub-investigator to be unsuitable for the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non febuxostat treatment group (Type: NO_INTERVENTION): No febuxostat treatment
- Febuxostat treatment group (Type: EXPERIMENTAL): once daily after breakfast

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Scar Location and Acute Haemodynamic Response to MultiPoint Pacing Study in Patients With Ischemic Cardiomyopathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18 years or over~* Previous STEMI (\> 3 months before enrolment) and consequent LV scar;~* Standard indication to CRT-D (NYHA functional class III-IV despite optimal medical therapy, LV ejection fraction (LVEF) ≤35 %, QRS duration ≥120 msec, LBBB);~* Sinus rhythm;~* Will and ability to give informed consent for participation in the study.~Exclusion Criteria:~* Pregnancy, trying for a baby or breast feeding;~* Any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study;~* Inability to tolerate MRI scanning (e.g. claustrophobia, unable to lie flat)~* Contraindications to MRI scanning (e.g. implantable devices, cranial aneurysm clips, metallic ocular foreign bodies, hypersensitivity to gadolinium);~* Significantly impaired renal function (eGFR \< 30ml/min);~* History of allergy to cardiac MRI contrast media;~* Severe claustrophobia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with myocardial scar (Type: OTHER): Patient with previous STEMI resulting in myocardial scar, elected to CRT implant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed adenocarcinoma of the pancreas~2. Patients is a candidate for gemcitabine chemotherapy (adjuvant, metastatic, locally advanced, borderline resectable settings all permitted)~3. Patients at least 18 years of age~4. ECOG performance status 0-2~5. Consent to donate 12 tubes of peripheral blood of 10 mL each~6. Adequate organ function as defined as -neutrophil count ≥ 1200 -platelets ≥ 75,000 -hemoglobin ≥ 8.0 -bilirubin ≤ 2.0 -creatinine ≤2.0 or calculated GFR ≥ 30~7. Ability to understand and willingness to sign a written informed consent document~8. Prior chemotherapy permitted, as long as 60 days have lapsed since last dose. Prior radiation therapy permitted, as long as 28 days lapsed since last treatment.~9. Patients may receive other concurrent chemotherapy, immunotherapy, or radiotherapy~Exclusion Criteria:~1. Patients never been immunized with tetanus toxoid (TT). Patients with a history of adverse reaction to tetanus vaccine (with the exception of self-limited fever or local tissue reaction~2. Patients may not be receiving any investigational agents~3. Pregnant women~4. Patients with HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Gemcitabine with TT vaccine booster (Type: EXPERIMENTAL): Gemcitabine will be delivered as is standard of care. Patients diagnosed with pancreatic ductal carcinoma (PCD) will be treated with Gemcitabine and boosted once with the human childhood vaccine to TT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Health-Related Quality of Life in Crohn's Disease Participants With Complex Perianal Fistula Before and After Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed with CD and CPF (defined as a fistula meeting any of the following criteria: high location \[high intersphincteric, high transsphincteric, extrasphincteric, or suprasphincteric\], multiple external openings, perianal abscess, anal stenosis, or proctitis).~2. Has tried and failed at least one prior treatment for CPF.~3. Starting a new pharmacological or surgical treatment for CPF.~Exclusion Criteria:~1. Diagnosed with indeterminate/unspecified type of inflammatory bowel disease (IBD).~2. Diagnosed with ulcerative colitis.~3. Diagnosed with fistula other than CPF (example rectovaginal).~4. Treated with darvadstrocel or other stem cells-based therapies within the eligibility period.~5. Previous fecal incontinence.~6. Lost to site follow-up for reasons other than death.~7. Participates or plans to participate in any interventional clinical trial.~8. Non fluent in Spanish.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All Participants (Type: None): Participants diagnosed with CD and CPF from approximately 20 Spanish hospitals, who will initiate medical or surgical treatment for their CPF within the eligibility period from Sep 2020 to Sep 2021, will be observed prospectively for approximately 31 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Clinical and Biomechanical Correlation During Return to Sport After Anterior Cruciate Ligament Injury

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* surgeon repair ACL injury ; sport practice ; signed informed consent~Exclusion Criteria:~* for injury subjects: pain during cutting tasks ; associated injury with ACL rupture~* for healthy subjects: history of ACL injury

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ACL injury (Type: EXPERIMENTAL): Subjects who has ACL injury repaired and who were allowed to return to sport
- Healthy subjects (Type: ACTIVE_COMPARATOR): Subjects who has never been injured in ACL and who practice sports with cutting task (soccer, handball)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal~* Locally advanced or metastatic hormone sensitive breast cancer with known estrogen receptor (ER) and progesterone receptor (PR) status~* Patient had a recurrence during or after adjuvant anti-oestrogen treatment or progression of the disease during anti-oestrogen treatment~Exclusion Criteria:~* Life threatening metastases

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Exploring the Effects of Lactobacillus Paracasei PS23 on Workplace-related Stress Symptoms Among Office Workers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Administrative staff of JARLLYTEC CO., LTD.~2. Age 20-65 years old~3. Those who feel that they are in a medium to high stress situation~Exclusion Criteria:~1. Have taken antibiotics within one month or are receiving antibiotic treatment~2. Have taken probiotic products within two weeks (excluding yogurt, yogurt, Yakult and other related foods)~3. have a history of cancer~4. Those who are allergic to lactic acid bacteria products~5. Those who are currently taking medication for acute illness, mental illness or sleep disorder~6. Pregnant or breastfeeding~7. The project host judges that it is not suitable to participate in the researcher

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- PS23 (Type: EXPERIMENTAL): 2 capsule daily
- Placebo (Type: PLACEBO_COMPARATOR): 2 capsule daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Stress Reduction Intervention for Women With Ischemic Heart Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of ischemic heart disease as defined by one or more of the following within the last 2 years:~* Positive stress test~* Admission for ACS, PCI, or CABG~* Typical or atypical ischemic symptoms within one month of enrollment~* On stable dose of anti-anginal medications for at least 2 months~* Able and willing to provide informed consent and comply with all aspects of the protocol~* Owns a smartphone with the ability to download applications for stress reduction and activity tracking~* English-speaking (apps are not available in other languages)~Exclusion Criteria:~* Planned for revascularization during the study period~* Self-reported or chart-reviewed diagnosis of psychotic disorder including schizophrenia or schizoaffective disorder, bipolar disorder~* Current participation in a cardiac rehab program or planned participation during the study period

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early Intervention (Type: EXPERIMENTAL): Stress reduction intervention 1 time a month
- Delayed Intervention (Type: EXPERIMENTAL): Wait list Control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Undergoing treatment for hematologic malignancies or HSCT as outlined below:~* Underlying diagnosis for non-HSCT patients:~* Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) receiving induction or reinduction chemotherapy; OR~* Acute lymphoblastic leukemia (ALL) receiving an intensive induction chemotherapy (e.g., HyperCVAD±R, CALGB9251, Larsons protocol) with an expected duration of neutropenia of ≥7 days; OR~* Allogeneic or autologous HSCT for any indication. For patients undergoing reduced intensity conditioning, only those regimens in which the expected neutropenia is ≥ 7 days are permitted and the patient must reside in the hospital~* Expected duration of neutropenia of ≥ 7 days~Exclusion Criteria:~* Use of anti infectives for treatment of active systemic infections within 7 days prior to initiation of study diet~* Untreated major infection at presentation~* Patients with uncontrolled invasive fungal infection (defined as those who have not completed at least 6 weeks of treatment; or who are symptomatic with two CT scans, at least 1 week apart showing uncontrolled disease at the time of initiation of study diet)~* Uncontrolled HIV, Hepatitis B and C infection~* Receipt of nutrition via enteral tube or total parenteral nutrition at the time of enrollment~* Patients unwilling to eat fresh fruit and/or vegetables~* Planned management of neutropenia in the outpatient setting

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liberalized Hospital Diet (Diet A) (Type: ACTIVE_COMPARATOR): Diet A would include fresh fruits and/or fresh vegetables in a liberalized hospital diet, and subjects will be encouraged to eat at least one daily serving of fresh fruits and/or vegetables.
- Neutropenic Diet (Diet B) (Type: ACTIVE_COMPARATOR): Diet B is the hospital neutropenic diet.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* Inclusion Criteria:~  1. Patients being treated with SU as 1st line treatment according to the approved therapeutic indication.~ 2. Histologically confirmed diagnosis of mRCC (clear cell RCC as well as nonclear cell RCC) with measurable disease according to RECIST 1.1~ 3. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.~     Exclusion Criteria:~  <!-- -->~  1. Patients being treated with cytokines or any other treatment other than SU in 1st line setting~ 2. Patients presenting with a known hypersensitivity to SU or its metabolites will not be included in the study per the label.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues